{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:15:50Z","timestamp":1793506550837,"version":"4.5.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side-effects based on the Grading of Recommendations Assessment, Development, and Evaluation system. As these drugs have been used for a relatively short time, large systematic investigations are scarce. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. We conclude that there is no clear evidence for the benefit of high-dose glucocorticoids to treat endocrine toxicities with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. With the exception of thyroiditis, most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation. Thus, the development of endocrinopathies does not dictate a need to stop ICI treatment.<\/jats:p>","DOI":"10.1530\/eje-22-0689","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:08:17Z","timestamp":1663931297000},"page":"G1-G21","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":202,"title":["Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-2976","authenticated-orcid":false,"given":"Eystein S","family":"Husebye","sequence":"first","affiliation":[{"name":"Department of Clinical Science and K.G. Jebsen Center of Autoimmune Diseases, University of Bergen , Bergen, Norway"},{"name":"Department of Medicine, Haukeland University Hospital , Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederik","family":"Castinetti","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, INSERM U1251, Marseille Medical genetics, Department of Endocrinology, Assistance Publique-Hopitaux de Marseille , 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Criseno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University of Milan, European Institute of Oncology, IRCCS , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Decallonne","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Pituitary Center, Department of Medicine and Neurological Surgery, Oregon Health & Science University , Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Higham","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Christie Hospital NHS Foundation Trust, University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Lupi","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Pisa University Hospital , Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A","family":"Paschou","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, ENETS Center of Excellence, Faculty of Medicine, Semmelweis University , Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"van der Kooij","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"2023012409131978800_bib1","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"2023012409131978800_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"2023012409131978800_bib3","first-page":"252","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature Reviews: Cancer"},{"key":"2023012409131978800_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocrine Reviews"},{"key":"2023012409131978800_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2023012409131978800_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"2023012409131978800_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"2023012409131978800_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"2023012409131978800_bib9","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"2023012409131978800_bib10","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2023012409131978800_bib11","first-page":"38","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nature Reviews: Disease Primers"},{"key":"2023012409131978800_bib12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncology"},{"key":"2023012409131978800_bib13","doi-asserted-by":"crossref","first-page":"708195","DOI":"10.3389\/fonc.2021.708195","article-title":"Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: a systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"2023012409131978800_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.08.020","article-title":"Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice","volume":"157","author":"Pinato","year":"2021","journal-title":"European Journal of Cancer"},{"key":"2023012409131978800_bib15","doi-asserted-by":"crossref","first-page":"847917","DOI":"10.3389\/fonc.2022.847917","article-title":"Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival","volume":"12","author":"Paschou","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"2023012409131978800_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocrine Journal"},{"key":"2023012409131978800_bib17","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"2023012409131978800_bib18","doi-asserted-by":"crossref","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectrum"},{"key":"2023012409131978800_bib19","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocrine Connections"},{"key":"2023012409131978800_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"2023012409131978800_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"},{"key":"2023012409131978800_bib22","first-page":"563","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nature Reviews: Clinical Oncology"},{"key":"2023012409131978800_bib23","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"2023012409131978800_bib24","first-page":"389","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nature Reviews: Endocrinology"},{"key":"2023012409131978800_bib25","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1530\/EJE-15-0625","article-title":"ESE guidelines, why and how","volume":"173","author":"Dekkers","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023012409131978800_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.zefq.2012.05.017","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"106","author":"Langer","year":"2012","journal-title":"Zeitschrift Fur Evidenz, Fortbildung und Qualitat Im Gesundheitswesen"},{"key":"2023012409131978800_bib27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M20-3419","article-title":"Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study","volume":"174","author":"van der Kooij","year":"2021","journal-title":"Annals of Internal Medicine"},{"key":"2023012409131978800_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncology"},{"key":"2023012409131978800_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"European Journal of Cancer"},{"key":"2023012409131978800_bib30","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Annals of Oncology"},{"key":"2023012409131978800_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"2023012409131978800_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ecl.2020.05.002","article-title":"A novel etiology of hypophysitis: immune checkpoint inhibitors","volume":"49","author":"Fernandes","year":"2020","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"2023012409131978800_bib33","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study","volume":"43","author":"Bai","year":"2020","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023012409131978800_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023012409131978800_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"2023012409131978800_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the growing spectrum of a rare pituitary disease","volume":"107","author":"Langlois","year":"2022","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib37","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clinical Diabetes and Endocrinology"},{"key":"2023012409131978800_bib39","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"2023012409131978800_bib40","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1210\/er.2009-0009","article-title":"The effects of opioids and opioid analogs on animal and human endocrine systems","volume":"31","author":"Vuong","year":"2010","journal-title":"Endocrine Reviews"},{"key":"2023012409131978800_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2019.06.020","article-title":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","volume":"119","author":"Mekki","year":"2019","journal-title":"European Journal of Cancer"},{"key":"2023012409131978800_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11547-019-01120-x","article-title":"Imaging findings in hypophysitis: a review","volume":"125","author":"Caranci","year":"2020","journal-title":"Radiologia Medica"},{"key":"2023012409131978800_bib44","doi-asserted-by":"crossref","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Scientific Reports"},{"key":"2023012409131978800_bib45","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/imj.12819","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series","volume":"45","author":"Lam","year":"2015","journal-title":"Internal Medicine Journal"},{"key":"2023012409131978800_bib46","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.3390\/jcm9103280","article-title":"Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up","volume":"9","author":"Levy","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"2023012409131978800_bib47","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fncel.2012.00024","article-title":"Synaptic regulation of the hypothalamic-pituitary-adrenal axis and its modulation by glucocorticoids and stress","volume":"6","author":"Levy","year":"2012","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"2023012409131978800_bib50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1530\/EC-17-0257","article-title":"Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement","volume":"6","author":"Smith","year":"2017","journal-title":"Endocrine Connections"},{"key":"2023012409131978800_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejim.2014.11.006","article-title":"A European Emergency Card for adrenal insufficiency can save lives","volume":"26","author":"Quinkler","year":"2015","journal-title":"European Journal of Internal Medicine"},{"key":"2023012409131978800_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000491388","article-title":"2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism","volume":"7","author":"Persani","year":"2018","journal-title":"European Thyroid Journal"},{"key":"2023012409131978800_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.beem.2013.10.003","article-title":"Pitfalls in the measurement and interpretation of thyroid function tests","volume":"27","author":"Koulouri","year":"2013","journal-title":"Best Practice and Research: Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2017-01899","article-title":"New neoplasm during GH replacement in adults with pituitary deficiency following malignancy: a KIMS analysis","volume":"103","author":"Krzyzanowska-Mittermayer","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-19-0535","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"182","author":"Bai","year":"2020","journal-title":"European Journal of Endocrinology"},{"key":"2023012409131978800_bib56","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Banas","year":"2020","journal-title":"Endocrine Connections"},{"key":"2023012409131978800_bib57","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"2023012409131978800_bib58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000501824","article-title":"Graves' disease induced by immune checkpoint inhibitors: a case report and review of the literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"European Thyroid Journal"},{"key":"2023012409131978800_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"key":"2023012409131978800_bib60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpt.1597","article-title":"Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a nationwide cohort","volume":"107","author":"Yang","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"2023012409131978800_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0394632015615130","article-title":"Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure","volume":"29","author":"Triggianese","year":"2016","journal-title":"International Journal of Immunopathology and Pharmacology"},{"key":"2023012409131978800_bib62","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib63","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2023012409131978800_bib65","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Annals of Oncology"},{"key":"2023012409131978800_bib66","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023012409131978800_bib67","doi-asserted-by":"crossref","first-page":"dgaa458","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","article-title":"Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes","volume":"64","author":"Peir\u00f3","year":"2019","journal-title":"Endocrine"},{"key":"2023012409131978800_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2023012409131978800_bib70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","article-title":"Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors","volume":"70","author":"Lima Ferreira","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"2023012409131978800_bib71","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023012409131978800_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid"},{"key":"2023012409131978800_bib73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"Journal of Neuroinflammation"},{"key":"2023012409131978800_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clinical Endocrinology"},{"key":"2023012409131978800_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye and Brain"},{"key":"2023012409131978800_bib76","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"2023012409131978800_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40123-020-00317-y","article-title":"Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with co-existing thyroid eye disease","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmology and Therapy"},{"key":"2023012409131978800_bib78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib79","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunology Research"},{"key":"2023012409131978800_bib80","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1089\/thy.2019.0799","article-title":"Immunoassay interference on thyroid function tests during treatment with nivolumab","volume":"30","author":"Paragliola","year":"2020","journal-title":"Thyroid"},{"key":"2023012409131978800_bib81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/fcp.12423","article-title":"Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance Database","volume":"33","author":"Garon-Czmil","year":"2019","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"2023012409131978800_bib82","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocrine Connections"},{"key":"2023012409131978800_bib83","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"2023012409131978800_bib84","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000356507","article-title":"2013 ETA guideline: management of subclinical hypothyroidism","volume":"2","author":"Pearce","year":"2013","journal-title":"European Thyroid Journal"},{"key":"2023012409131978800_bib85","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1603825","article-title":"Thyroid hormone therapy for older adults with subclinical hypothyroidism","volume":"376","author":"Stott","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"2023012409131978800_bib86","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib87","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Research and Care"},{"key":"2023012409131978800_bib88","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"2023012409131978800_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Hormone and Metabolic Research"},{"key":"2023012409131978800_bib90","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"2023012409131978800_bib91","doi-asserted-by":"crossref","first-page":"2654.e1","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clinical Therapeutics"},{"key":"2023012409131978800_bib92","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00262-018-2178-0","article-title":"Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and\/or anti-CTLA-4) for metastatic melanoma: a retrospective study","volume":"67","author":"Gauci","year":"2018","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"2023012409131978800_bib93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fendo.2017.00106","article-title":"Review of evidence for adult diabetic ketoacidosis management protocols","volume":"8","author":"Tran","year":"2017","journal-title":"Frontiers in Endocrinology"},{"key":"2023012409131978800_bib94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocrine Practice"},{"key":"2023012409131978800_bib95","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"2023012409131978800_bib96","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"2023012409131978800_bib97","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"Journal of the Endocrine Society"},{"key":"2023012409131978800_bib98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison's disease: a rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"European Journal of Cancer"},{"key":"2023012409131978800_bib99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1530\/EDM-16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"2023012409131978800_bib100","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/0140-6736(92)91829-W","article-title":"21-Hydroxylase, a major autoantigen in idiopathic Addison's disease","volume":"339","author":"Winqvist","year":"1992","journal-title":"Lancet"},{"key":"2023012409131978800_bib101","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib102","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/jc.2017-02602","article-title":"The short cosyntropin test revisited: new normal reference range using LC-MS\/MS","volume":"103","author":"Ueland","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12032-020-01357-x","article-title":"Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer","volume":"37","author":"Ida","year":"2020","journal-title":"Medical Oncology"},{"key":"2023012409131978800_bib104","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1210\/clinem\/dgaa256","article-title":"Residual corticosteroid production in autoimmune Addison disease","volume":"105","author":"S\u00e6vik","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib106","doi-asserted-by":"crossref","first-page":"e000687","DOI":"10.1136\/jitc-2020-000687","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib107","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/clinem\/dgaa092","article-title":"Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib108","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2023012409131978800_bib110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"Journal of Oncology Practice"},{"key":"2023012409131978800_bib111","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"American Journal of Emergency Medicine"},{"key":"2023012409131978800_bib112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"2023012409131978800_bib113","doi-asserted-by":"crossref","first-page":"7459268","DOI":"10.1155\/2020\/7459268","article-title":"Hypocalcemia with immune checkpoint inhibitors: the disparity among various reports","volume":"2020","author":"Nalluru","year":"2020","journal-title":"International Journal of Endocrinology"},{"key":"2023012409131978800_bib114","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1530\/EC-19-0163","article-title":"Programmed death ligand 1 (PD-L1) expression in parathyroid tumors","volume":"8","author":"Pan","year":"2019","journal-title":"Endocrine Connections"},{"key":"2023012409131978800_bib115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12894-021-00825-4","article-title":"Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report","volume":"21","author":"Johnson","year":"2021","journal-title":"BMC Urology"},{"key":"2023012409131978800_bib116","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023012409131978800_bib117","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicologic Pathology"},{"key":"2023012409131978800_bib118","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/pds.5103","article-title":"Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data","volume":"29","author":"Gilsenan","year":"2020","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"2023012409131978800_bib119","first-page":"376","article-title":"Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review","volume":"67","author":"Van den Driessche","year":"2009","journal-title":"Netherlands Journal of Medicine"},{"key":"2023012409131978800_bib120","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1210\/jc.2009-1368","article-title":"Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry","volume":"94","author":"Erichsen","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409131978800_bib121","first-page":"379","article-title":"Clinical and immunological characteristics of autoimmune Addison disease: a nationwide Swedish multicenter study","volume":"102","author":"Dalin","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/6\/EJE-22-0689.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/6\/EJE-22-0689.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/6\/G1\/48837762\/eje-22-0689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/6\/G1\/48837762\/eje-22-0689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:18:22Z","timestamp":1676373502000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/6\/G1\/6979880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":121,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-22-0689","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,10,25]]}}}